An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia-Myelofibrosis (PET-MF)
ID Number 12-1018Principal Investigator(s)
John O. Mascarenhas
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called INCB039110. An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies. The purpose of this research study is to determine the effects of INCB039110 on spleen size and symptoms and to learn about any of the side effects that might occur while taking the study drug and after you stop taking the study drug.
Recruiting Patients: Yes